amelenodor (NX-13) - Landos Biopharma
NX-13: "NX-13 was well-tolerated & shows promising signs of clinical improvement in active UC"; Ulcerative colitis (Landos Biopharma) - Apr 30, 2024 - Corporate Presentation 
P1 data • Inflammatory Bowel Disease • Ulcerative Colitis
https://ir.landosbiopharma.com/static-files/c99d4848-5216-4776-91f2-6a81e0cdf5b1
 
Apr 30, 2024
 
 
0d3c9655-90f3-4fd5-8308-4a8463e51dd7.png

c3b1c0f5-7445-4764-b023-5c2b49838cba.png